An international consortium of researchers has unveiled a groundbreaking neural interface technology that could significantly advance the precision of brain research and pave the way for innovative treatments for complex neurological conditions such as epilepsy. Developed through a collaborative effort involving the Technical University of Denmark (DTU), the University of Copenhagen, and University College London (UCL), the newly engineered device—known as the microfluidic Axialtrode, or mAxialtrode—combines optical fibers, electrical recording channels, and fluid delivery systems into a single, needle-thin implant. Published in the peer-reviewed journal Advanced Science, the research introduces a paradigm shift in how scientists can interact with and monitor living neural tissue. By integrating multiple functional modalities into a polymer-based fiber measuring less than half a millimeter in diameter, the team has successfully addressed several longstanding limitations associated with conventional neuroscientific instrumentation. While currently deployed exclusively as an advanced research instrument to investigate neural signal propagation, memory formation, and decision-making pathways, the long-term clinical potential of the mAxialtrode spans the targeted delivery of therapeutics alongside simultaneous optical and electrical stimulation. Background Context and Technological Evolution The development of the mAxialtrode arrives at a critical juncture in the fields of neuroengineering and clinical neurology. For decades, researchers investigating the functional architecture of the brain have relied heavily on rigid silicon-based electrodes and traditional optical fibers made of glass or hard plastics. While these legacy tools have yielded fundamental insights into neurophysiology, they suffer from inherent material and functional constraints. Rigid implants often provoke chronic inflammatory responses and glial scarring within the soft tissue of the central nervous system due to the mechanical mismatch between hard silicon and delicate brain matter. Furthermore, conventional optical fibers are typically restricted to surface-level interactions or single-point interventions at their distal tips. This single-site limitation forces researchers to either insert multiple independent devices—thereby increasing tissue trauma—or compromise on the spatial resolution of their observations. The mAxialtrode overcomes these barriers by merging microfluidics, electrophysiology, and optogenetics into a unified, flexible platform. The genesis of the concept traces back to collaborative discussions between DTU Postdoc Kunyang Sui and Associate Professor Christos Markos. Recognizing the need for a multimodal tool that minimizes invasiveness while maximizing data collection and therapeutic delivery channels, the team engineered a manufacturing process capable of producing complex fiber architectures with microscopic precision. Chronology and Development Timeline The path to the mAxialtrode required a multi-stage, cross-disciplinary development timeline spanning several years of materials engineering, microfabrication, and in vivo validation: Conceptualization and Design: DTU researchers Kunyang Sui and Christos Markos conceptualized the multi-functional fiber design, focusing on soft polymer alternatives to traditional silicon and glass to mitigate inflammatory tissue responses. Microscale Fabrication: The team refined a thermal drawing process, heating a macroscopic polymer preform and drawing it down into an ultra-thin, flexible fiber while preserving internal microfluidic channels and structural integrity. Integration of Multimodal Capabilities: Engineers embedded a light-conducting core, eight microfluidic liquid-transport channels, and ultra-thin metallic recording wires into a fiber measuring less than 0.5 millimeters across. Preclinical In Vivo Testing: In collaboration with neurophysiologists Associate Professor Rune W. Berg of the University of Copenhagen and Associate Professor Rob C. Wykes of University College London, the device underwent rigorous in vivo testing in living murine models. Neurophysiological Validation: Researchers successfully demonstrated simultaneous multi-depth electrical recording, dual-color optical stimulation (using red and blue light), and site-specific fluid delivery spanning a span of nearly three millimeters. Publication and Intellectual Property: The findings were published in Advanced Science, while the research consortium initiated patent filings for the core technology and began exploring pathways toward clinical translation. Anatomy of the mAxialtrode The manufacturing process of the mAxialtrode represents a notable technical achievement in materials science. The fabrication begins with a macroscopic polymer rod—a preform—containing the macroscopic blueprints of the internal architecture. By applying precise thermal energy and controlled mechanical tension, the researchers draw the preform down into an exceptionally fine, flexible fiber, mirroring the principles of optical fiber production but with vastly increased structural complexity. Running directly through the geometric center of the finished fiber is a specialized light-conducting core capable of transmitting photons deep into subcortical structures. Surrounding this optical pathway are eight microscopic fluidic channels. These channels serve a dual purpose: they can transport minute quantities of liquid medications, neurotransmitters, or chemical agents, and they can house ultra-thin metallic wires designed to capture electrical signals generated by firing neurons. The final outer diameter of the mAxialtrode is maintained at a fraction of a millimeter. Because it is constructed from soft, polymer-based materials rather than brittle glass or rigid silicon, the implant possesses a mechanical compliance that closely matches biological neural tissue. This flexibility allows the device to flex and move in tandem with natural micro-motions of the brain, substantially reducing mechanical stress and subsequent neuroinflammatory reactions during long-term implantation. Preclinical Validation and In Vivo Performance To evaluate the efficacy and biocompatibility of the mAxialtrode under realistic physiological conditions, the research team conducted comprehensive in vivo experiments utilizing living mice. The surgical implantation involved securing the microfluidic optical fiber into targeted regions of the murine brain, connecting the proximal end to external light sources, electrophysiological recording equipment, and precision miniature fluid pumps. During the testing phase, the implanted subjects carried the lightweight fiber assembly freely without demonstrating behavioral abnormalities, distress, or impaired mobility. Neurophysiological monitoring confirmed that the central optical core successfully delivered both blue and red light to activate targeted nerve cells via optogenetic protocols. Simultaneously, the embedded metallic channels recorded high-fidelity electrical activity across multiple distinct brain layers, successfully capturing neural dynamics within both superficial cortical areas and deeper subcortical structures such as the hippocampus. Crucially, the microfluidic capabilities were tested by injecting precise fluid volumes at varying depths along the length of a single implant, with delivery sites spaced approximately three millimeters apart. This ability to concurrently stimulate optically, record electrically, and administer chemical agents across a distributed vertical axis represents a substantial technical leap over existing single-point probes. Implications for Epilepsy and Neuroscientific Research The collaborative input from neurocircuitry experts Rune W. Berg and Rob C. Wykes ensured that the experimental validation directly addressed questions relevant to complex neurological disorders, most notably epilepsy. Epilepsy is characterized by aberrant, hypersynchronous electrical discharges originating within localized neural networks that can rapidly propagate across multiple brain regions. Effectively studying and eventually treating such dynamic pathologies requires tools capable of monitoring network-wide activity while intervening with high spatial and temporal resolution. The mAxialtrode offers a unique methodological framework for epilepsy research. By enabling researchers to observe how electrical signals travel through distinct cortical and subcortical layers during seizure-like events—while simultaneously deploying pharmacological agents or optical neural silencing protocols directly to the epileptogenic focus—the device provides a comprehensive platform for dissecting seizure mechanisms. Beyond epilepsy, the technology holds broad implications for basic neuroscience, memory consolidation studies, and closed-loop neuromodulation therapies. Closed-loop systems, which monitor real-time brain activity and automatically deliver therapeutic interventions (such as electrical stimulation or anti-convulsant drugs) the moment an abnormal pattern is detected, could be significantly enhanced by the multiplexed capabilities of soft, multi-channel fibers. Pathways to Clinical Translation and Future Outlook Despite the promising preclinical results demonstrated in living animal models, the research team emphasizes that the mAxialtrode remains in the developmental phase. Translating an implantable neurotechnology from a laboratory prototype to a clinically approved medical device is a rigorous, multi-year endeavor requiring extensive safety evaluations, chronic biocompatibility studies, scale-up manufacturing validation, and comprehensive regulatory clearance from agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Future research efforts by the DTU and university consortium will focus on optimizing the long-term durability of the polymer fibers, refining automated fluid delivery mechanisms, and expanding preclinical trials to larger animal models whose brain architecture more closely approximates that of humans. Concurrently, the institution is actively pursuing patent protection for the core innovations underpinning the mAxialtrode to facilitate commercial partnerships and eventual clinical translation. As the boundaries between materials science, microfluidics, and neurophysiology continue to blur, innovations such as the mAxialtrode underscore the accelerating pace of neuroengineering. By providing scientists with a less invasive, highly multiplexed window into the living brain, this technology brings the scientific community one step closer to decoding complex neural circuits and developing sophisticated, targeted therapies for some of medicine’s most challenging neurological conditions. Post navigation Beyond the Morning Mug: How Coffee and Decaf Reshape the Gut-Brain Axis and Mood
